 <b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> Under 37 CFR 1.97(b) or 1.97(c)		Docket No. 2462-131US	
In Re Application Of: <b>Kazuya Hosokawa</b>			
Serial No. <b>10/018,251</b>	Filing Date <b>14 December 2001</b>	Examiner	Group Art Unit
<b>Title: METHOD AND SUBSTANCE FOR INHIBITING REACTION BETWEEN ACTIVATED BLOOD COAGULATING FACTOR AND SUBSTRATE</b>			
<p style="text-align: center;">Address to:                      Commissioner for Patents                      P.O. Box 1450                      Alexandria, VA 22313-1450</p> <p style="text-align: center;"><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;"><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="margin-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center; margin-left: 100px;"><b>OR</b></p> <p style="margin-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>			

# TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

JUN 20 2003

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
2462-131US

In Re Application: Kazuya Hos kawa

Serial No.

10/018,251

Filing Date

14 December 2001

Examiner

Group Art Unit

## METHOD AND SUBSTANCE FOR INHIBITING REACTION BETWEEN ACTIVATED BLOOD

### Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **23-3040** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

#### Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

*[Signature]*

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

#### Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on June 18, 2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*[Signature]*

Signature of Person Mailing Correspondence

Richard C. Woodbridge

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

*[Signature]*


Signature

Dated:

June 18, 2003

Richard C. Woodbridge  
Woodbridge & Associates, P.C.  
P.O. Box 592  
Princeton, NJ 08542  
609-924-3773  
609-924-1811

CC:



ATTY DOCKET NO.

2462-131US

SERIAL NO.

10/018,251

FILING

14 December 2001

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A	EP 0 882 789 A	09/12/1998	EP				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	B	Tomono T Et Al: "Preparation of Anhydro-Thrombin and its Interaction with Plasma Antithrombin III", Acta Haematologica, S. Karger, Basel, Ch, vol. 49, no. 4, July 1986 (1986-07), pages 969-979
	C	Ashton R. W. et al: "Preparation and Characterization of Anhydrothrombin" Biochemistry, Consultants Bureau, New York, NY, US, vol. 34, no. 19, 1995, pages 6456-6463

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 20 2003

ATTY DOCKET NO.

2462-108

SERIAL NO.

**10/018,251**

FILING

**14 December 2001**

GROUP

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

		D	Nogami Keiji et al: "Role of Factor VIII C2 Domain in Factor VIII Binding to Factor Xa." Journal of Biological Chemistry, vol. 274, no. 43, 22 October 1999 (1999-10-22), pages 31000-31007

**EXAMINER**

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.